Abstract. The treatment of choice for esophageal cancer is considered surgical resection, but a median survival of around 20 months after treatment is still discouraging. The value of adjuvant or neoadjuvant radiation or chemotherapy is limited and to date, benefits have only been described for certain tumor stages. Therefore, new therapeutic options are required. As alternative chemotherapeutics, we tested the antibiotic taurolidine (TRD) on KYSE 270 human esophageal carcinoma cells alone and in combination with rhTRAIL (TNF related apoptosis-inducing ligand). Viability, apoptosis and necrosis were visualized by TUNEL assay and quantitated by FACS analysis. Gene expression was analysed by RNA microarray. The most effective concentration of TRD as single substance (250 μmol/l) induced apoptosis to a maximum of 40% after 12-h dose dependently, leaving 4% viable cells after 48 h; by comparison, rhTRAIL did not have a significant effect. The combination of both substances doubled the effect of TRD alone. Gene expression profiling revealed that TRD downregulated endogenous TRAIL, TNFRSF1A, TRADD, TNFRSF1B, TNFRSF21, FADD, as well as MAP2K4, JAK2 and Bcl2, Bcl2l1, APAF1 and caspase-3. TNFRSF25, cytochrome-c, caspase-1, -8, -9, JUN, GADD45A and NFKBIA were upregulated. TRAIL reduced endogenous TRAIL, Bcl2l1 and caspase-1 expression. BIRC2, BIRC3, TNFAIP3, and NFKBIA were upregulated. The combined substances upregulated endogenous TRAIL, NFKBIA and JUN, whereas DFFA and TRAF3 were downregulated compared to TRD as single substance. We conclude that TRD overcomes TRAIL resistance in KYSE 270 cells. Synergistic effects are dependent on the same and on distinct apoptotic pathways which, jointly triggered, result in an amplified response. Several apoptotic pathways, including the TNF-receptor associated and the mitochondrial pathway, were differentially regulated by the substances on gene expression level. Additionally transcription factors seem to be influenced, NFKB in particular. Endogenous TRAIL expression is increased by the combination of substances, whereas it is reduced by each single substance. Taking into consideration that the non-toxic TRD was able to reduce rhTRAIL toxicity and dose, combined therapy with TRD and rhTRAIL may offer new options for treatment in esophageal cancer.
Introduction
The carcinoma of the esophagus with a stage dependent survival of rarely >50% still represents a therapeutic challenge especially concerning the fact that its incidence is rising. Treatment of esophageal carcinoma is based on individualised and stage specific multimodal approaches which comprise esophagectomy as well as neoadjuvant, adjuvant or palliative chemotherapy and radiation. Despite this broad multidisciplinary armamentarium, the overall survival is still poor and problems such as primary or acquired resistance against chemotherapy or side effects remain unsolved (1) (2) (3) (4) (5) (6) (7) (8) . New treatments such as immunotherapy and hyperthermia so far have also failed to improve the outcome significantly (9) (10) (11) (12) (13) (14) . For unresectable tumors the effects of chemotherapy and radiotherapy may prolong survival in some cases, but side effects are severe and life quality remains poor (15) (16) (17) (18) .
To elucidate new options for treatment we tested two promising agents rhTRAIL (recombinant human tumor necrosis factor associated apoptosis inducing ligand) and taurolidine (TRD) seperately and in combination on esophageal squamous cancer cells (KYSE 270) in vitro.
TRAIL as a physiological apoptosis inducing molecule of 33 kD belongs to the TNF super-family and seems to be involved in the natural antitumoral and antiviral immunoresponse (19) . TRAIL initiates cell death by binding to the transmembraneous death receptors 4 and 5 (DR4, DR5), thereby inducing the binding of the intracellular adaptor molecule FADD (Fas associated death domain) and starting a cascade involving caspase-8 to form the so-called DISC (death-inducing signalling complex) which is activating several effector caspases. Another type of cell death induction by TRAIL via the intrinsic, mitochondrial pathway leading to a cytochrome-c efflux from mitochondria, formation of apoptosomes and activation of the effector caspases has also been described (19) (20) (21) (22) (23) (24) (25) (26) . In contrast to many other chemotherapeutics, TRAIL induces apoptosis independently from p53 (21, 27, 28) . Binding of TRAIL to the decoy receptors 1 and 2 (DcR1, DcR2) that, in contrast to DR4 and DR5, lack a transmembraneous death domain, probably results in a competitive inhibition of apoptosis (19, 29) . Several recombinant versions of TRAIL have been generated and some were shown to induce apoptosis in healthy hepatocytes and keratinocytes (30, 31) . In contrast, a new recombinant human TRAIL (rhTRAIL) without any added exogenous sequences has been shown to be well tolerated by mice and non-human primates without relevant side effects (20, 32) . Many substances, including established chemotherapeutics such as 5-Fluorouracil, cisplatin, doxorubicin, etoposide, have been shown to sensitize tumor cells including esophageal cancer cells to TRAIL-induced apoptosis probably by increased DR4 and DR5 expression, improved DISC formation and other mechanisms (33) (34) (35) (36) (37) (38) (39) .
Taurine is a semi-essential amino acid and is not incorporated into proteins. In mammalian tissues, taurine is ubiquitous and is the most abundant free amino acid in the heart, retina, skeletal muscle, brain and leukocytes. It protects normal tissue from oxidant-induced injury and apoptosis (40) . TRD, derived from Taurine, originally was used as an antimicrobial and antiinflammatory substance in the treatment of peritonitis and blood stream infections without any observed short-or long-term toxicity (41) (42) (43) . Recent studies revealed an apoptotic effect on a variety of malignant cells in vitro and in vivo, including colon, ovarian, prostate carcinoma, melanoma, mesothelioma, osteosarcoma and leukemia (44) (45) (46) (47) (48) (49) (50) (51) (52) . First reports of successful treatments of glioblastoma and gastric cancer without systemic side effects in humans are promising (53) (54) (55) . The detailed mechanism of action is still unclear, but inhibition of Bcl-2 and an increased efflux of cytochrome-c, activation of the caspases, and an increased PARP (poly(ADP-ribose) polymerase) cleavage seem to be involved (44, 48, 49, 51, 52, 56) . By comparison, other authors found Fas-ligand dependent mechanisms or inhibition of tumor angiogenesis to be responsible for the inhibition of tumor growth (57) (58) (59) .
The absence of toxicity and its apoptosis inducing potential make TRD a candidate for co-treatment with TRAIL, hypothetically increasing its apoptotic effects. To our knowledge, a combination of rhTRAIL and TRD has not yet been investigated on esophageal cancer cells.
Materials and methods
Cell line. Human esophageal squamous cancer cells, Kyse 270, were purchased from DSMZ (Braunschweig, Germany) and maintained with 48% RPMI-1640 + 48% Ham's F12 + 2% FBS supplemented with 1% penicillin (100 U/ml) and streptomycin (100 μg/ml) and 1% L-Glutamine. Cells were cultured in a humidified atmosphere with 5% CO 2 at 37˚C on 6-well plates with 1x10 6 cells/well (subconfluent).
Reagents. TRD (Taurolin ® 2%, Boehringer Ingelheim, Germany) containing 5% Povidon was used as supplied by the manufacturer. A 5% Povidon solution (K16 Povidon, generously provided by Geistlich Pharma AG, Wolhusen, Switzerland) was applied in equal volume and served as a control for the TRD group. Recombinant human TRAIL/ Apo2L (Bender MedSystems, Vienna, Austria) was dissolved in distilled water according to the manufacturer's instructions. Distilled water served as a control for TRAIL and was applied in equal volume.
Dose-finding study. Cells were incubated with TRD (10, 50, 100, 250 and 500 μmol/l) or recombinant human TRAIL (50, 100, 250 and 500 ng/ml) and the respective controls (Povidon/H 2 O) for 1, 3, 6, 12, 24 and 48 h to identify the most effective single concentrations and the time dependency of the effects. All experiments were repeated with 3 passages.
Additionally different concentrations of TRAIL (10, 100, 250 and 500 ng/ml) were combined with TRD 100 μmol/l in another experiment for 1, 3, 6, 12, 24 and 48 h to quantitate the effects of different TRAIL concentrations when combined with TRD. All experiments were repeated with 3 passages.
The most effective single concentrations of TRD and TRAIL were then used as single substances and in combination to identify a possibly synergistic effect. Three, 6 and 12 h were chosen as time points. All experiments were repeated with 3 passages. Cells for gene expression were harvested after 12 h, representing the time of maximal apoptosis. Oligonucleotide microarray analysis. Total RNA was purified from the cells after incubation with the different substances for 12 h using the RNeasy KIT from Qiagen (Hilden, Germany), as specified by the manufacturer. RNA integrity was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies). For microarray analyses we used the Affymetrix GeneChip platform employing a standard protocol for sample preparation and microarray hybridization. Total RNA (5 μg) was converted into biotinylated cRNA according to the Affymetrix standard protocol version 2, purified, fragmented and hybridized to HG-U133Plus_2.0 microarrays (Affymetrix). The arrays were washed and stained according to the manufacturer's recommendation and finally scanned in a GeneChip scanner 3000 (Affymetrix).
Array images were processed to determine signals and detection calls (Present, Absent, Marginal) for each probe set using the Affymetrix GCOS1.4 software (MAS 5.0 statistical algorithm). Arrays were scaled across all probesets to an average intensity of 1000 to compensate for variations in the amount and quality of the cRNA samples and other experimental variables of non-biological origin. Pairwise comparisons of treated versus control samples were carried out with GCOS1.4, which calculates the significance (change p-value) of each change in gene expression based on a Wilcoxon ranking test. To limit the number of false positives, we restricted further target identification to those probe sets, which received at least one present detection call in the treated/control pair. Probe sets exhibiting a significant increase or decrease were identified by filtering using the Affymetrix Data Mining Tool 3.0.
Results

TRD induces apoptotic cell death in esophageal cancer cells.
Concentrations below 100 μmol/l (10 and 50 μmol/l) did not lead to significant apoptosis or necrosis, even after incubation for 48 h. The higher concentrations (100, 250 and 500 μmol/l) initiated apoptotic cell death after 3-6 h of incubation, reaching a maximum of detectable apoptosis between 12 and 24 h. The highest and most early rates of apoptosis were found for a concentration of 250 μmol/l with 40% apoptotic cells after 12 h. This concentration also led to the highest necrosis rates, with >80% after 48 h. At this time, only 4% of the cells were left viable (Fig.1) . 
TRAIL as single agent does not induce apoptotic cell death in esophageal cancer cells.
The concentrations of TRAIL that were used (50, 100, 250 and 500 ng/ml) did not lead to any detectable significant increase in apoptosis. After 6 h, an increase of necrotic cells to a maximum of 12% at 24 h was detected with a TRAIL concentration of 500 ng/ml; however, this effect was not significant. The proportion of viable cells remained above 86% after 48 h of incubation with the highest concentration of TRAIL (Fig. 2) .
A combination of TRAIL and TRD amplifies apoptotic effects.
When the lowest TRD concentration that was found to be effective (100 μmol/l) in the previous experiment was combined with different concentrations of TRAIL (50, 100, 250 and 500 ng/ml), 500 ng/ml of TRAIL was the most potent, reaching a maximum of almost 29% apoptotic cells after 12 h. After 48 h, 62% of the cells were found to be necrotic and 21% were still viable (Fig. 3) .
A combination of the most effective single doses (250 μmol/l TRD and TRAIL 500 ng/ml) reduces viable cells to 25% within 12 h. Compared to the single use of 250 μmol/l TRD, the addition of TRAIL 500 ng/ml doubles the effect. The reduction of viable cells as well as the induction of apoptosis was significantly increased by TRD and TRAIL, compared to the control and compared to the single use of TRD (Fig. 4) .
The dot blots of the FACS analysis demonstrated that cells were undergoing apoptotic cell death, showing Annexin V positivity in the early phases of incubation and an additional PI positivity at the later time points, representing a shift from early apoptosis to cell death and necrosis (Fig. 5 ).
Taurolidine and TRD/TRAIL induce morphological changes, cell detachment and TUNEL positivity. TRAIL incubation did not change the cell morphology, or cause a detachment of the cells from the ground neither did it influence the TUNEL staining results. The combination of TRD and TRAIL resulted in disintegration of the subconfluent cell groups and shrinkage of the cells, followed by complete cell detachment (Fig. 6) . TUNEL staining was negative for the controls, showed a few positive cells in the TRD treated cultures, and a noticeable increase of stained cells in the TRD/TRAIL group. Nuclear fragmentation and apoptotic bodies were also detectable in this group (Fig. 7) .
Gene expression. In this experiment we selectively focussed on apoptosis related probesets. Out of 621 of those probesets 266, representing 186 apoptosis related genes showed expression changes. TRD alone induced differences in the reading of 213 probe sets, representing 154 apoptosis related genes, of which 66 were 'upregulated'; whereas TRAIL as a single substance caused changes in 12 probe sets standing for 9 genes related to apoptotic pathways, 'upregulating' 6 of them. TRD and TRAIL in combination induced overexpression of 17 and 'downregulation' of 17 (22 probe sets each) compared to TRD as single substance (Fig. 8) . Due to the multitude of differential regulated genes, only a representative selection of genes is mentioned in detail. N-terminal kinase kinase 1), Janus kinase 2 (JAK2), Bcl-2, Bcl2l1/ BclxL, apoptotic peptidase activating factor (APAF1) and caspase-3 'downregulated'.
Caspase-1, -8, -9, cytochrome-c, poly(ADP-ribose) polymerase family 1 (PARP1), tumor necrosis factor receptor super-family 25 (TNFRSF25), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (NFKBIA), growth arrest and DNA-damage-inducible gene alpha (GADD45A) and v-jun sarcoma virus 17 oncogene homolog (JUN/AP-1) were 'upregulated'.
Cells exposed to TRAIL 'downregulated' TNFSF10 (TRAIL), Bcl2l1 and caspase-1. Baculoviral IAP repeatcontaining 2 (BIRC2), BIRC3, tumor necrosis factor alphainduced protein 3 (TNFAIP3) and NFKBIA were 'upregulated'.
When the TRD/TRAIL incubated cells were compared to the cells only receiving TRD, DNA fragmentation factor, 45 kDa, alpha polypeptide (DFFA), TNF receptor-associated factor 3 (TRAF3) were 'downregulated'. TNFSF10 (TRAIL), NFKBIA and JUN/AP-1 were 'upregulated'. A summary of all genes associated with apoptosis by Gene Ontology is shown in Table I .
Discussion
Taurolidine. A concentration of 100 μmol/l was the lowest effective to induce apoptotic cell death in squamous esophageal cancer cells. The most effective concentration (reaching the peak of apoptotic cells the earliest) was 250 μmol/l. Apoptosis was detectable after 3-6 h and reached its maximum at 12 h; it then decreased and gave way to necrosis that reached a maximum after 48 h with >80%. The fact that 250 μmol/l TRD was more effective than 500 μmol cannot be explained but may be interpreted as an indication for an apoptotic mechanism rather than a necrotic one.
Many of the factors, 'downregulated' by TRD, belong to the TNF receptor associated death signalling pathway, such as endogenous TRAIL, TNFRSF1A, TRADD, TNFRSF1B, TNFRSF21, FADD and downstream of that pathway MAP2K4.
The receptors TNFRSF1A and TNFRSF1B are transducers of TNF action and lead to programmed cell death via TRADD and FADD activation (60) . Crosstalk between TNFRSF1A and TNFRSF1B (a regularly non-apoptotic receptor lacking a death domain) via endogenous TNF was shown to induce apoptosis and activate MAP2K4 and NFKB (61) (62) (63) . TNFRSF21 (Death receptor 6, DR6) a recently identified member of the TNF receptor family, induces apoptosis via a FADD-independent mechanism and can be inhibited by increased levels of Bcl-2 (64).
MAP2K4/c-Jun N-terminal kinase kinase 1, which was also 'downregulated' by TRD, is a proapoptotic factor of the JNK transcription factors cascade also being activated by the TNF receptor system (65) . Another anti-apoptotic tyrosine kinase JAK2, whose blockade has already been shown to inhibit tumor growth and induce apoptosis (66) and to sensitize cells to TRAIL induced apoptosis (67), was also 'downregulated' by TRD.
The inhibition of Bcl2 and Bcl2l1 expression by TRD may be responsible for an increased efflux of cytochrome-c and thereby positively correlates with increased complexformation with APAF 1 and consecutive caspase-9 activation Table I . Continued.
----------------------------------------------------------------------------------------------------Probe set Gene symbol TRD vs. control TRAIL vs. control TRD/TRAIL vs. control TRD/TRAIL vs. TRD ----------------------------------------------------------------------------------------------------
- Table I . Continued.
- Table I . Continued. -0.8 Table I . Continued. TRD interacted with the mitochondrial pathway also by 'upregulation' of cytochrome-c expression, which is known to activate the caspase cascade as mentioned above. Within the TNF-receptor system TNFRSF25/DR3, a death receptor binding to FADD and thereby triggering apoptosis (69) was found to be 'upregulated'.
----------------------------------------------------------------------------------------------------Probe set Gene symbol TRD vs. control TRAIL vs. control TRD/TRAIL vs. control TRD/TRAIL vs. TRD -----------------------------------------------------------------------------------------------------
GADD45A, a potent inhibitor of the c-Jun N-terminal kinase (JNK) cascade and NFKB, inhibits transcription factors associated with tumor growth (65, (70) (71) (72) and was 'upregulated' by TRD. Additionally GADD45 may antagonize TNF-receptor mediated cytotoxicity (70) . The transcriptional factor JUN, that was 'upregulated' in the TRD and the TRAIL treated cells, is known to be a product of MAP2K4-activation and to mediate apoptosis by several chemotherapeutics (71, 73) .
TRAIL.
No concentration of TRAIL as a single substance had a significant influence on the treated cells concerning apoptosis or necrosis within the observed time frame of 48 h, indicating that KYSE 270 squamous esophageal cancer cells are primary TRAIL resistant.
Accordingly, the influence of TRAIL as a single substance on gene expression was moderate. Only caspase-1 and Bcl2l1, which affect the cytochrome-c efflux in a similar way as Bcl-2 and endogenous TRAIL, were 'downregulated'. Coinciding with our gene expression profile findings, TRAIL is known to increase the expression of antiapoptotic mediators such as BIRC2/IAP2 and BIRC3/API2 in some malignant cells, probably via an inactivation of NFKB (74, 75) . TNFAIP3, that was found to be 'upregulated' by TRAIL in our study, is an inhibitor of NFKB and may thereby promote apoptosis, but on the other hand TNFAIP3 was shown by other authors to decrease TNF-mediated apoptosis (76) , leaving its specific influence unclear.
As previously shown, the members of the TNF family, such as TRAIL, also have many non-apoptotic functions e.g. activating transcription through NFKB and JUN/AP-1 leading to induction of immunomodulatory and inflammatory genes (77) , involving TRADD and FADD, which are also known as mediators of several apoptotic pathways (78) (79) (80) . Crosstalking to these other pathways and activating transcription factors may be unselective and partly explain possible toxic effects of TRAIL on non-malignant cells (81) . Interestingly, TRD was shown to reduce toxicity of TNF in vivo without reducing its antitumoral activity probably by interfering not with TNF directly but with its down-stream pathway which is largely the same for TRAIL (82, 83) . Accordingly, TRD, among other effects, inhibits the activation of NFKB, which is a potent signal trans-ducer for inflammatory cytokines, by oxidation of IκB-α at Met45 (40) .
NFKB is activated TRADD-, TRAF3-and FADDdependently (72) and also plays a key role in the survival of tumor cells by inducing expression of anti-apoptotic genes such as Bcl2, Bcl2l1, vascular endothelial growth factor (VEGF) and X-linked inhibitor of apoptosis (XIAP). In physiological conditions, NFKB is sequestered in inactive form by inhibitory proteins such as NFKBIA (84) (85) (86) .
Another indication for the relevance of NFKB for the observed TRD and TRAIL mediated apoptosis is the fact that NFKBIA was 'upregulated' by combination of TRAIL and TRAIL/TRD. TRD/TRAIL. When TRAIL was added to TRD, we detected a highly significant increase in apoptotic and non-viable cells compared to the control and to TRD alone. The kinetics remained unchanged compared to TRD alone. TRAIL (500 ng/ml) proved to be the most effective concentration for the combined use with TRD 100 μmol/l, leaving only 79% of the cells viable after 48 h. In the direct comparison of the most potent single concentrations as mono-substance and the combination-treatment, a synergistic effect of TRAIL (500 ng/ml) and TRD (250 μmol/ml) with a bisection of the remaining living cells after 12 h was observed.
The synergistic effects of the combination of TRD and TRAIL may be caused by an activation of the same and of distinct apoptotic pathways, such as the TNF-receptor and the mitochondrial one, which, jointly triggered, result Table I . Continued.
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Signal log ratios of the changes are given for the several samples (TRD vs. control, TRAIL vs. control, TRD/TRAIL vs. control, TRD/TRAIL vs. TRD), signal log ratio of 1 representing a 2-fold increase, one of -1, that the expression is half of the expression of the control group and so forth.
in an amplified response. However, the effects of the single substances and the gene expression profiles of the cells, treated with the combination TRD and TRAIL, point to NFKB as a key factor in apoptosis, mediated by these substances. When the TRD/TRAIL results were compared to TRD alone, we found endogenous TRAIL 'upregulated', whereas it was 'downregulated' by TRD and TRAIL as single substances. TRAF3 as an activator of NFKB was 'downregulated'; NFKBIA as an inhibitor of NFKB was 'upregulated'. JUN, that was 'upregulated' in the TRAIL and in the TRD/TRAIL treated cells, is known to be a product of MAP2K4-activation and to mediate apoptosis by several chemotherapeutics, but has also been associated with antiapoptotic effects (73, 87) . While all death receptors as well as the described transcription factors can activate both apoptotic and non-apoptotic pathways, it has been widely assumed that the main physiological role of FADD-binding death receptors is to trigger apoptosis (69) and of NFKB to have mainly anti-apoptotic effects (85) .
The 'downregulation' of DFFA may be associated with the TRD dependent 'downregulation' of caspase-3, which has been shown to be responsible for activation of DFFA (88) . Altogether, as shown by the FACS analysis, the antiapoptotic effects of the combination therapy detected in the microarray analysis were greatly outweighed by the cell death inducing ones, suggesting that important factors for the synergistic effects may be increased TRAIL and decreased NFKB activity.
We conclude that the increased activation of the mitochondrial and the TNF-receptor associated pathway as well as the inhibition of crucial transcription factors qualify the TRD/TRAIL combination therapy for further studies, especially taking into consideration that other chemotherapeutics that could amplify the effect of TRAIL or sensitize resistant cells to TRAIL show considerable toxicity (35, 89) . However, there is evidence that TRD may not only add to the apoptotic effect of TRAIL but also decrease its possible toxic side effects by pathway modulation.
